| 发明名称 |
Method of treatment |
| 摘要 |
The present invention relates to a method of treating T cell mediated inflammatory immune diseases or T cell mediated hypersensitivity diseases, which comprises administering to a human in need thereof an effective amount of a compound which inhibits EZH2 and/or EZH1, or a pharmaceutically acceptable salt thereof. |
| 申请公布号 |
US9446041(B2) |
申请公布日期 |
2016.09.20 |
| 申请号 |
US201514953546 |
申请日期 |
2015.11.30 |
| 申请人 |
GlaxoSmithKline Intellectual Property (No. 2) Limited |
发明人 |
Bassil Anna K.;Beinke Soren;Prinjha Rabinder Kumar |
| 分类号 |
A61K31/496;C12N9/10;A61K31/4439;C07D401/14;A61K31/405 |
主分类号 |
A61K31/496 |
| 代理机构 |
|
代理人 |
Fitch Duke M.;Lutomski Kathryn A.;Gimmi Edward R. |
| 主权项 |
1. A method of treating a T cell mediated inflammatory immune disease, selected from a group consisting of solid organ transplant rejection and graft versus host disease, comprising administering to a human in need thereof an effective amount of a compound which is N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl-1-[(1S)-1-methylpropyl]-6-[6-(1-piperazinyl)-3-pyridinyl]-1H-indole-4-carboxamide, or a pharmaceutically acceptable salt thereof. |
| 地址 |
Brentford, Middlesex GB |
